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Abstract
Background: Late-stage chronic kidney disease (LS-CKD) can be defined by glomerular filtration rate (GFR) 0–30 mL/min. It is
a period of risk for medication discrepancies because of frequent hospitalizations, fragmented medical care, inadequate
communication and polypharmacy. In this study, we sought to characterize medication discrepancies in LS-CKD.
Methods: We analyzed all patients enrolled in Northwell Health’s Healthy Transitions in LS-CKD program. All patients had
estimated GFR 0–30 mL/min, not on dialysis. Medications were reviewed by a nurse at a home visit. Patients’ medication
usage and practice were compared with nephrologists’ medication lists, and discrepancies were characterized. Patients
were categorized as having either no discrepancies or one or more. Associations between patient characteristics and
number of medication discrepancies were evaluated by chi-square or Fisher’s exact test for categorical variables, and
two-sample t-test or Wilcoxon text for continuous variables.
Results: Seven hundred and thirteen patients with a median age of 70 (interquartile range 58–79) years were studied.
There were 392 patients (55.0% of the study population) with at least one medication discrepancy. The therapeutic classes
of medications with most frequently occurring medication discrepancies were cardiovascular, vitamins, bone and mineral
disease agents, diuretics, analgesics and diabetes medications. In multivariable analysis, factors associated with higher
risk of discrepancies were congestive heart failure [odds ratio (OR) 2.13; 95% confidence interval (CI) 1.44–3.16; P ¼ 0.0002]
and number of medications (OR 1.29; 95% CI 1.21–1.37; P < 0.0001).
Conclusions: Medication discrepancies are common in LS-CKD, affect the majority of patients and include high-risk
medication classes. Congestive heart failure and total number of medications are independently associated with
greater risk for multiple drug discrepancies. The frequency of medication discrepancies indicates a need for great care
in medication management of these patients.
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Introduction
Medication discrepancies can be defined as a mismatch
between a treating physician’s understanding of patients’ current medications (including dose and frequency) and the actual
medications that the patient takes. Discrepancies have the
potential to impair the effectiveness and safety of medication
treatment. Ideally, the physician conducts a medication reconciliation with the patient and educates patients about medications. In addition, the physician should maintain good
communication with other medical providers regarding medication changes. In actual practice, however, medication discrepancies are frequent, occurring in 34–95% of patients at the
time of admission for acute hospitalizations or psychiatric clinics [1, 2]. When discrepancies occur there may be failure to recognize symptoms and signs as medication side effects and
increased risk for adverse events [3]. A systematic review of
acute hospitalizations found that 11–59% of medication discrepancies were clinically important and 39% had potential to cause
moderate-to-severe patient harm [1].
To date there have been no studies of medication discrepancies in late-stage chronic kidney disease (LS-CKD). LS-CKD can
be defined as CKD Stages 4–5, prior to the initiation of renal
replacement therapy. There are several reasons to suspect that
medication discrepancies may be common in LS-CKD. Patients
often take multiple medications, reaching a mean of 11.8 by the
time of dialysis need [4]. Polypharmacy and conflicting dosing
schedules are never easy for patients to manage. This is probably more true in LS-CKD, where patients are usually older and
have comorbidities including cognitive decline. In addition,
patients with LS-CKD often have multiple different physicians
involved in their care. The result can sometimes be care fragmentation with confusion created by numerous drug and dosing changes. Frequent hospitalizations among patients with LSCKD result in medication and dose changes, often without
adequate reconciliation and communication among providers
at hospital discharge. In general, communication problems are
a recurring theme throughout the care system, contributing to
medication risk.
Since 2012, we have operated the Healthy Transitions care
management program for patients with LS-CKD. Nephrologist
treatment is supplemented by nursing care management services and advanced informatics. All program patients have an
initial home visit, which offers a unique opportunity for medication review. The visit occurs as the initial program contact, so
the medication reviews are free from any interventional effect.
At the visit, the patient and key caregivers show the bottles of
medications being used and explain how many pills are taken
and how frequently. Because this occurs in the patient’s home,
with the actual drugs consumed, it is a rigorous form of medication review. In this analysis, we sought to utilize this uniquely
clear view of medication use to better understand and characterize the frequency, type and risk factors for medication discrepancies in LS-CKD. We are aware of no previous studies of
this subject in CKD and studies in other populations have often
relied on health record reviews rather than direct patient interviews [5, 6].

Materials and methods
Patient population
The Healthy Transitions in Late Stage Kidney Disease program
began operation in October 2012. The program provides nursing

care management services to patients with LS-CKD, in an effort
to facilitate care processes and improve preparation for endstage kidney disease (all such patients were eligible for participation in the program). The program includes patients with
CKD Stages 4–5 defined as estimated glomerular filtration rate
(eGFR) 0–30 mL/min, and excludes patients (i) on dialysis and
(ii) with significant cognitive impairment, defined as need for
assistance with activities of daily living. The program began as
a pilot, entered a full implementation phase and subsequently
had an imbedded randomized controlled trial (RCT) [7] and a
3-year period of funding by Centers for Medicare and Medicaid
Innovation program Health Care Innovations Award.
All patients enrolled throughout all program phases from
October 2012 to December 2016 were included in the current
analysis except for patients from the RCT control group. The
justification for inclusion of all of these program phase patients
is that all had exactly the same initial home visit with medication review conducted prior to any other interventions. The program functions and patients were enrolled, from Nassau,
Suffolk, Queens, Kings and New York counties of New York
State. There have been seven different participating nephrology
groups. Three of the offices were private practices, four were
academic nephrology practices. There was no standardized
method for medication history-taking among the nephrologists.

Medication review
Medication discrepancies were defined from the perspective of
the nephrologist. Most patients had a recent visit with the
nephrologist at the time of program enrollment. After enrollment, a home visit was conducted by a program nurse. The
nephrologist’s medication list was printed from the electronic
health record (EHR) prior to the home visit. All program nephrologists’ EHRs prompt for medication reconciliation at all
patient visits.
Medication reviews were all conducted by one of the program’s registered nurses. All took place during an initial home
visit that occurred prior to any other program interventions.
The purpose of the home visit is to begin to build a trusting relationship, to assess the patient’s knowledge regarding their kidney disease, to initiate education regarding modality options for
renal replacement therapy and diet and most relevant to the
current analysis, to conduct a complete medication review.
The medication portion of the visit begins with the nurse
asking the patient and key care giver where in the home medications are kept, and how the patient carries medications if
needed during the day. Next, the patient was asked to remove
their currently used medication jars from their medicine cabinet or other storage area. In many cases, the nurse helped the
patient with this task. Each medication jar was reviewed individually with attention to accuracy. The patient was questioned
on (i) if the medication was currently being taken, (ii) how many
pills, (iii) how many times a day and (iv) were there any other
medications, including over-the-counter agents, herbals or vitamins, that the patient took. The patient was questioned on
other medications that were on the nephrologist’s medication
list but that the patient was not taking at that time. For any difference between the nephrologist’s list of medications and the
patient’s actual medication consumption, a discrepancy and its
characteristics were recorded. Although all patients had subsequent medication reviews as part of the program, only the baseline review was included in the current analysis to avoid
potential bias introduced by program interventions.

Medication discrepancies in LS-CKD

Table 1. Patient characteristics
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Table 2. Frequency distribution of number of medication discrepancies per patient

Characteristic

n (% or SD)

Mean age (years)
Male
Race
White
Black
Other or multiracial
Asian
Hispanic ethnicity
Hypertension
Diabetes
Congestive heart failure
Primary insurance type
Medicare
Private
Medicaid
No insurance
Active smoker
Yes
No
Not specified
Mean eGFR (mL/min)
eGFR category (mL/min)
<10
10–15
15.1–20
>20
Mean number of medications

67.5 (15.9)
403 (56.5)
434 (60.9)
174 (24.4)
67 (9.4)
38 (5.3)
64 (9.0)
662 (92.8)
364 (51.1)
181 (25.3)
400 (56.1)
239 (33.5)
67 (9.4)
7 (1)
41 (5.8)
666 (93.4)
6 (0.8)
18.6 6 6.4
52 (7.3)
188 (26.4)
178 (25)
295 (41.4)
8.1 (3.4)

Statistical analyses
Baseline patient demographics (age, gender, race, ethnicity,
hypertension, diabetes, congestive heart failure, insurance type,
smoking status and eGFR) were described using categorical or
continuous variables as appropriate. In the entire patient
cohort, the frequency, proportion and type of medication discrepancy was described. Categorization of medication discrepancy type was determined a priori, and included therapeutic
class, and any difference between the nephrologist’s list of
medications and the patient’s actual medication consumption
(i.e. patient taking medication not on nephrologist’s list, patient
not taking medication on nephrologist’s list, different dose and/
or different frequency, drug discontinued and patient taking,
drug discontinued and still on nephrologist’s list or patient not
taking medication as instructed).
To evaluate patient characteristics associated with risk for
multiple medication discrepancies, we first divided patients
into two categories, one with no medication discrepancies and
one with one or more discrepancies. We decided on categorization prior to any inspection of results by category. The variables
chosen for study were based on availability and then on those
with potential causal pathways. In an initial univariable analysis, we used chi-square or Fisher’s exact test as appropriate for
categorical variables, and two-sample t-test or Wilcoxon text as
appropriate for continuous variables, to evaluate the association of each patient characteristic with the outcome of number
of medication discrepancies (no discrepancies versus one or
more). In subsequent multivariable logistic regression analysis,
factors that were found statistically significant in the univariable analysis plus age and gender were taken as the candidate
variables for the final model. We conducted all analyses using
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

Medication discrepancies per patient

Number

Percentage

0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

321
125
83
57
41
19
24
14
4
5
8
3
3
1
2
1
1
0
1

45.0
17.5
11.6
8.0
5.8
2.7
3.4
2.0
0.6
0.7
1.1
0.4
0.4
0.1
0.3
0.1
0.1
0.0
0.1

Results
A total of 713 patients were reviewed who were enrolled from
October 2012 to December 2016. In the entire cohort, the median
age was 70 [interquartile range (IQR) 58–79] years, 56.5% were
men, 24.4% were black, 60.9% were white, 9% were Hispanic,
51.1% were diabetic and 92.8% had hypertension. Patient characteristics are displayed in Table 1. The distribution of eGFR
was <10 mL/min, 7.3%; 10–15 mL/min, 26.3%; 15.1–20 mL/min,
25%; > 20 mL/min, 41.4%. Six patients had previously undergone
kidney transplantation. The median time from last nephrologist
medication reconciliation to nurse visit was 3 (IQR 1–6) days.
There were 392 patients (55.0% of the study population) with
at least one medication discrepancy. The total number of discrepancies was 1280, and the median number of discrepancies
per patient (in patients with at least 1 discrepancy) was 2 (IQR
1–4). The distribution of discrepancies per patient is displayed
in Table 2. There were 321 patients with zero discrepancies
(45%), 125 patients with one discrepancy and 83 patients with
two discrepancies. There were 12.1% of patients with five or
more discrepancies. The most common type of discrepancies
were patients taking a medication not on nephrologist’s list
(49.1% of discrepancies), patients not taking a medication on
the nephrologist’s list (22.7%), different dose (18.4%) and different frequency (5%) (Figure 1). The therapeutic medication
classes with the greatest number of discrepancies were cardiovascular (15.5% of discrepancies), vitamins (11.0%), bone and
mineral disease agents (8.9%), diuretics (7.0%), analgesics (6.7%)
and diabetes medications (5.0%) (Figure 2). The types of discrepancies were similar for different drug classes. Among cardiovascular drugs, the subcategories with the greatest number of
discrepancies were renin angiotensin aldosterone system inhibitors (66% of cardiovascular discrepancies) and beta blockers
(24%).
When assessing the outcome of multiple medication discrepancies, there were 321 patients with no discrepancies, and
392 patients with one or more discrepancies. In a univariable
analysis, the following patient characteristics were found to be
associated with medication discrepancies (P < 0.05): congestive
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Fig. 1. Frequency distribution of types of medication discrepancy, from most common to least common.
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Fig. 2. Frequency of medication discrepancies by therapeutic class.

heart failure, white race, hypertension and number of medications taken (Table 3). In subsequent multivariable logistic
regression analysis, factors that were found statistically significant in the univariable analysis plus age and gender were taken
as the candidate variables for the final model. After backward
variable selection, factors in the final model independently
associated with higher risk of one or more medication discrepancies compared with zero discrepancy were congestive heart
failure [odds ratio (OR) 2.13; 95% confidence interval (CI) 1.44–
3.16; P ¼ 0.0002] and number of medications (OR 1.29; 95% CI
1.21–1.37; P < 0.0001) (Table 4).

Discussion
We found that more than half of patients with LS-CKD had at
least one discrepancy between the nephrologist’s medication
record and the medications actually being consumed.
Approximately one-third of patients had two or more discrepancies. Most discrepancies were related to medications being

taken that were not on the nephrologist’s list, medications on
the nephrologist’s list that were not being taken, and dose and
frequency differences.
Effective medication management is achieved by optimizing
the benefits and reducing risks of treatment. Ongoing medication review and reconciliation by the provider is essential for
longitudinal maintenance of medication safety. When discrepancies develop between the medications that the provider
intends for the patient to be taking and those actually being
used, there is increased risk for loss of efficacy or adverse
events. Discrepancies can be highly relevant, with a recent
study finding that in intensive care units, 17.1% of discrepancies
were serious or potentially life-threatening [8].
In the treatment of patients with LS-CKD, the medication
management process is fraught with polypharmacy, extensive
comorbidity and altered medication pharmacology due to
reduced renal function, fragmented medical care and frequent
hospitalizations. The nephrologist plays a key and often principal role in maintenance of medication safety in these patients.

Medication discrepancies in LS-CKD

Table 3. Univariate association of patient characteristics and number of medication discrepancies

Patient characteristics
Mean number of
discrepancies (SD)
Mean (6SD) age (years)
Gender, n (%)
Male
Female
Race, n (%)
White
Black
Other or multiracial
Asian
Hispanic ethnicity, n (%)
Yes
No
Hypertension, n (%)
Yes
No
Diabetes mellitus, n (%)
Yes
No
Congestive heart
failure, n (%)
Yes
No
Current smoker, n (%)
Yes
No
Not specified
Insurance status, n (%)
Medicaid
Medicare
No insurance
Private
Mean (6SD) eGFR (mL/min)
Mean (6SD) number of
medications
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Table 4. Multivariable analysis for medication discrepancy (logistic
regression)

Number of medication
discrepancies

Multivariable analysis for medication discrepancy

Zero
discrepancies 1 discrepancy
(n ¼ 321)
(n ¼ 392)
P-value

Variables

Odds ratio
(95% confidence interval)

P-value

CHF (yes versus no)
Number of medications

2.13 (1.44–3.16)
1.29 (1.21–1.37)

0.0002
<0.0001

0

3.3 (2.8)

NA
CHF, congestive heart failure.

68.0 6 15.8

67.3 6 16.1

172 (42.7)
149 (48.1)

231 (57.3)
161 (51.9)

177 (40.8)
89 (51.2)
33 (49.3)
22 (57.9)

257 (59.2)
85 (48.9)
34 (50.8)
16 (42.1)

33 (51.6)
288 (44.4)

31 (48.4)
361 (55.6)

289 (43.7)
32 (62.8)

373 (56.3)
19 (37.2)

163 (44.8)
158 (45.3)

201 (55.2)
191 (54.7)

0.40
0.15

0.03

0.27

0.01

0.90

0.0004
61 (33.7)
260 (48.9)

120 (66.3)
272 (51.1)

20 (48.8)
298 (44.7)
3 (50.0)

21 (51.2)
368 (55.3)
3 (50.0)

37 (55.2)
180 (45.0)
4 (57.1)
100 (41.8)
19.1 6 6.6
6.8 6 2.3

30 (44.8)
220 (55.0)
3 (42.9)
139 (58.2)
18.3 6 6.2
9.2 6 3.8

0.82

0.23

0.08
<0.0001

Our finding of a high rate of medication discrepancies signifies
an important gap in performance and opportunity for improvement in LS-CKD. The fact that more than one-third of patients
had two or more discrepancies is a strong indicator of the magnitude of the problem.
It is concerning that cardiovascular medications were the
most commonly discrepant class of medication and diuretics
the fourth most common, because of the hemodynamic and
metabolic effects of these agents. This aligns with the finding
that congestive heart failure as comorbidity was a key independent predictor of multiple discrepancies. It is likely that concordant cardiac disease creates important vulnerabilities in
medication management in LS-CKD. The diseases complicate
and confound treatment of each other. Medications such as
renin angiotensin aldosterone system inhibitors and diuretics
are adjusted frequently in response to cardiac, renal or electrolyte disturbances. When the medications are changed, communication between physicians may often be suboptimal. This

complex, chaotic setting is fertile ground for medication discrepancies and complications.
We also found that the number of medications that patients
were taking was associated with greater risk for discrepancies.
This is an intuitive finding and consistent with existing knowledge [9]. In LS-CKD, patients take a large number of medications
and it is wise to review ongoing need for all chronic medications.
Reduction in medication discrepancies in LS-CKD requires a
more intensive approach to medication reconciliation. Sharing of
medication information between healthcare providers and accurate is a prerequisite. Incorporation of pharmacy information on
medication fill histories into EHRs holds great promise [10]. Ideally,
the physician’s medication record should reflect the time of the
last patient visit or other communication, but annotated with subsequent activity from other providers and pharmacies. Improved
patient education is important as well, as it is probable that better
understanding of medications and their purpose would enhance
patient adherence and limit errors. Polypharmacy is certainly an
issue as well. The mean number of medications taken by LS-CKD
patients is substantial. Elimination of unnecessary medications
should be an ongoing effort to improve patient safety.
Strengths of our study include the large numbers of patients
in different types of practice settings. In addition the determination of medication discrepancies was by a highly rigorous
approach with home visits and review of actual medication bottles and usage descriptions by the patient and key caregivers.
Limitations include the geographically limited region covered,
the metropolitan New York counties of Nassau, Suffolk,
Queens, Kings and Manhattan. In addition, there was underrepresentation of individuals with Hispanic ethnicity. Hispanic
patients made up only 9% of the study population, compared
with 17% of the US population. The dataset had a low proportion of missing data in that 15% of discrepancies were accompanied by insufficient documentation of the specific involved
medication. In addition, we were unable to determine which
discrepancies might create a higher level of risk to patients as
no available classification scheme is reliable. Additionally, we
were not able to identify potential intentional discrepancies, for
example, if a second physician had changed a medication.
Finally, our dataset also did not allow for determination of the
underlying reasons for unintentional medication discrepancies.
In conclusion, we found a high rate of medication discrepancies in LS-CKD. There is a need to better understand the subject
to help improve medication management and reduce risk for
medication errors. Future research efforts should focus on
whether discrepancies relate to patient outcomes and on causative factors for medication discrepancies.
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